About reVax

About reVax

REGiMMUNE’s reVax technology "re-educates" the immune system by inducing immune regulatory cells. reVax technology specifically suppresses the immune system target while maintaining normal immune reaction. In contrast, current technologies such as immunosuppressants broadly down-regulate the immune system, which can cause negative effects including risk of serious infection and toxicity. In addition, reVax works not only as a treatment, but can work as a vaccine in a prophylactic mode, without the need for adjuvants. Traditional vaccine therapies enhance immunoprotective ability against an antigen by immunizing it with a specific adjuvant, which itself can cause negative effects.

Immune system

Immune system

In the past few decades, breakthroughs in biotechnology, genomics and basic science have led to a better understanding of the human immune system and researchers have discovered new ways to treat diseases that affect the immune system. The immune system is a network of organs, glands, and tissues that protects the body from foreign substances. These substances include bacteria, viruses, and other infection-causing parasites and pathogens. Usually, the immune system is extremely effective in performing its work of defending the body, but sometimes an error occurs in this highly complex system, and it can lead health problems. The result can be a simple allergic reaction, as serious as a fatal condition such as cancer or the error can manifest as an autoimmune disorder, such as RA or SLE, in which the body rejects its own constituents as foreign invaders.

The functioning of the immune system also calls into play a wide array of substances, most notably antibodies and the two significant varieties of lymphocyte: B cells and T cells. Antibodies, the most well known of the three, are proteins in the human immune system that help fight foreign invaders. B cells (B lymphocytes) are a type of white blood cell that gives rise to antibodies, whereas T cells (T lymphocytes), are a type of white blood cell that plays an important role in the immune response. T cells are a key component in the cell-mediated response, the specific immune response that utilizes T cells to neutralize cells that have been infected with viruses and certain bacteria. There are three types of T cells: cytotoxic, helper, and suppressor T cells. Cytotoxic T cells destroy virus-infected cells in the cell-mediated immune response, whereas helper T cells play a part in activating both the antibody and the cell-mediated immune responses. Suppressor T cells deactivate T cells and B cells when needed, and thus prevent the immune response from becoming too intense.

Immune tolerance

The human immune system is designed to attack foreign invasion of disease-causing organisms while it protects normal function by way of unresponsiveness. Tolerance is the key mechanism of the specific unresponsiveness and is maintained by a subset of regulatory T cells called TregTolerance is a direct way to treat immune disorders that are caused by excessive immune reaction against antigens. REGiMMUNE is currently developing products that induce Treg, which leads to antigen specific immune tolerance.

reVax induces Treg

REGiMMUNE’s proprietary technology platform reVax targets immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg).

reVax technology uniquely enables target-specific immune suppression,by tolerance induction. Unlike existing immune suppressants which broadly and excessively suppress immunity and cause subsequent issues such as infection and tumor progression, reVax suppresses only unfavorable immune reaction. reVax technology uniquely enables target-specific immune suppression,by tolerance induction.

α-GalCer

α-GalCer is a glycolipid. It is a CD1d ligand originally isolated from the marine sponge and developed as an anti-tumor agent. It was evaluated in healthy volunteers and oncology patients and shown to have a good safety profile. Because α-GalCer was found to expand and activate natural killer (NKT) cells and subsequently, Treg, it was later developed as an immune-modulator. A liposomal formulation of α-GalCer injected with an antigen induces regulatory T cells efficiently and leads to an antigen specific immune tolerance. Preclinical models have demonstrated efficacy in many autoimmune disorders including GvHD, TIDM, RA, MS, and SLE. Results from both clinical and preclinical studies have been published in more than 1,000 papers in peer review journals.

reVax fomulation

reVax fomulation

reVax technology uniquely enables target-specific immune suppression,by tolerance induction. Unlike existing immune suppressants which broadly and excessively suppress immunity and cause subsequent issues such as infection and tumor progression, reVax suppresses only unfavorable immune reaction. reVax technology uniquely enables target-specific immune suppression,by tolerance induction. Unlike existing immune suppressants which broadly and excessively suppress immunity and cause subsequent issues such as infection and tumor progression, reVax suppresses only unfavorable immune reaction.